Skip to main content

Eli Lilly, Novo Nordisk and Sanofi CEOs to testify before Senate on lowering insulin prices

Eli Lilly, Novo Nordisk and Sanofi control 90% of the insulin market in the U.S, where a quarter of all health care spending is on people with diabetes.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.